InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

Not yet recruitingLast updated: 12 February 2024

SABRE: This study is investigating whether receiving an injection prior to radiation therapy reduces gastrointestinal toxicity in people with prostate cancerEffectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy

Clinical summary


Eligible participants will be randomly allocated to one of two arms.

In Arm A, participants will recieive radiation therapy after an injection of the SpaceOAR Vue hydrogel. The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiation therapy for prostate cancer with the intention of reducing the radiation dose delivered to the anterior rectum. The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiation therapy treatment and is completely absorbed by the patient's body over time.

In Arm B, participants will receive radiation therapy without the use of the SpaceOAR Vue. 


This trial is treating patients with prostate cancer who have been planning to undergo stereotactic body radiotherapy (SBRT)


Urinary System Cancers Genitourinary




Not applicable

Trial Acronym


More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Boston Scientific Corporation

Scientific Title

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy



  • Age ≥ 18 years old.
  • Subjects must have pathologically confirmed (by routine hematoxylin and eosin (H&E) staining) invasive adenocarcinoma of the prostate and been planning to undergo SBRT.
  • Subjects must have intermediate risk prostate cancer as defined by the presence of one or more of the following:
  • Clinical Stage T2b - T2c (AJCC 6th edition) tumor
  • Gleason Score 7 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
  • Demonstrated blood PSA levels 10-20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
  • Subject or authorized representative was informed of the nature of the study and provided written informed consent, approved by the appropriate Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site.


  • Prostate >80 cc documented within 9 months preceding Enrollment (randomization)
  • Clinical stage T3 or T4 (AJCC 6th edition) tumor
  • Blood PSA level >20 ng/ml as measured within 6 months preceding Enrollment (randomization) and prior to commencing androgen deprivation therapy (ADT)
  • Gleason Score ≥ 8 as determined from a biopsy taken within 9 months preceding Enrollment (randomization)
  • Subjects who had MRI evidence of gross posterior extracapsular extension (ECE) of the prostate cancer. (Note: MRI should be from within 9 months preceding Enrollment (randomization). If MRI is contraindicated, a digital rectal exam may be performed to confirm the absence of gross posterior ECE)
  • Subjects who had metastatic disease, other ongoing cancers which were treated during the study or subjects for whom pelvic lymph node radiotherapy was planned.
  • Subjects with any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject had been disease free for a minimum of 3 years.
  • History of prostatectomy, transurethral prostate surgery (e.g. TUNA, TUMT, TURP) if performed within 1 year prior to screening, other local prostate cancer therapy (e.g., cryotherapy or brachytherapy) or previous pelvic irradiation at any time prior to screening.
  • History of prior pelvic surgery requiring low anterior or abdominoperineal resections or rectal surgery.
  • History of or active inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis.
  • History of or current perirectal disease that may interfere with interpretation of study outcomes including anal or perianal diseases such as fistula.
  • Bleeding hemorrhoids requiring medical intervention within the prior three months.
  • Diagnosed active bleeding disorder or a clinically significant coagulopathy. Note: Patients on anticoagulants may be included if the anticoagulant medication can be discontinued for index procedure.
  • Active inflammatory or infectious process involving the perineum, gastrointestinal (GI) or urinary tract based on positive diagnosis or suspected diagnosis in the presence of fever >38⁰ C, WBC > 12,000/uL.
  • Compromised immune system or prior diagnoses for human immunodeficiency virus (HIV) (with a detectable viral load within the last 6 months)/acquired immunodeficiency syndrome (AIDS) or autoimmune disease.
  • If a subject was enrolled in another investigational drug or device trial that had not completed the primary endpoint or that clinically interfered with this study.
  • Unable to comply with the study requirements or follow-up schedule.
  • Any condition the Investigator believed would interfere with the intent of the study or would make participation not in the best interest of the patient.
  • Known iodine sensitivity or allergy
  • Known polyethylene glycol (PEG) sensitivity or allergy


  • Your cancer has not spread to other parts of the body.


  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

Not yet recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support


Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more


Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more


Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.


Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.